Last reviewed · How we verify
NTX/PBO-B
NTX/PBO-B is a combination of naltrexone (an opioid antagonist) and bupropion (an antidepressant) designed to reduce appetite and promote weight loss.
NTX/PBO-B is a combination of naltrexone (an opioid antagonist) and bupropion (an antidepressant) designed to reduce appetite and promote weight loss. Used for Chronic weight management in obese or overweight adults with weight-related comorbidities.
At a glance
| Generic name | NTX/PBO-B |
|---|---|
| Sponsor | Alkermes, Inc. |
| Drug class | Combination antiobesity agent (opioid antagonist + antidepressant) |
| Target | Opioid receptors (naltrexone); norepinephrine and dopamine transporters (bupropion) |
| Modality | Small molecule |
| Therapeutic area | Obesity / Metabolic Disease |
| Phase | Phase 3 |
Mechanism of action
Naltrexone blocks opioid receptors in the hypothalamus, removing tonic inhibition of pro-opiomelanocortin (POMC) neurons that regulate satiety. Bupropion, a norepinephrine-dopamine reuptake inhibitor, enhances the activity of these POMC neurons. Together, the combination increases energy expenditure and decreases hunger, leading to sustained weight reduction.
Approved indications
- Chronic weight management in obese or overweight adults with weight-related comorbidities
Common side effects
- Nausea
- Constipation
- Headache
- Dizziness
- Insomnia
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NTX/PBO-B CI brief — competitive landscape report
- NTX/PBO-B updates RSS · CI watch RSS
- Alkermes, Inc. portfolio CI